Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX versus TAZICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX versus TAZICEF.
CEFIZOX vs TAZICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefizox (ceftizoxime) is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and autolysin inhibition.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to cell lysis and death.
1-2 g IV/IM every 8-12 hours; maximum 12 g/day for severe infections.
2 g intravenously every 8 hours for serious infections; 1 g intravenously every 8 hours for uncomplicated infections.
None Documented
None Documented
1.7-1.9 hours in adults; prolonged to 15-25 hours in severe renal impairment (CrCl <10 mL/min)
2 hours (prolonged to 4-12 hours in renal impairment; anuria: 20-30 hours).
Primarily renal (90-95% unchanged via glomerular filtration and tubular secretion); biliary (<1%); fecal (minimal)
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic